ebook Munafa Stock Market Course + Intraday & FNO calls  

       

524816 announcements Natco Pharm announcements and dividends declared BSE

Natco Pharm Complete list of announcements declared & dividend announcements by Natco Pharm 524816

Natco Pharm 524816 listed on BSE and deals in

Announcements and dividends declared by Natco Pharm 524816

Here's why HDFC Securities recommends buying VRL Logistics, Natco Pharma
Logistics stocks have been showing strength on the medium term charts, according to Vinay Rajani of HDFC Securities.
Announcement as on 12 January 2022

Natco Pharma plans to launch Molnupiravir capsules this week for treatment of COVID-19
Molnupiravir is the first COVID-19 drug authorised by the Drugs Controller General of India (DCGI) for the treatment of COVID-19 infection in adults who have high risk of progression of the disease including hospitalisation or death.
Announcement as on 28 December 2021

Natco Pharma proposes to acquire Dash Pharmaceuticals
According to a press release issued by the Hyderabad-based drug maker, Dash is a front-end pharmaceutical sales, marketing and distribution entity based in New Jersey, USA which is expected to have approximate net sales of USD 15 million for the year endin
Announcement as on 14 December 2021

Natco Pharma launches novel fixed-dose combination drug for colorectal, gastric cancer
Natco Pharma has launched a novel fixed-dose combination of Trifluridine and Tipiracil, used to treat advanced colorectal and gastric cancer, in the country. The company has launched the product under the brand name Tipanat in a pack of 20 tablets in a bot
Announcement as on 18 November 2021

Natco Pharma launches novel drug for colorectal, gastric cancer
Natco Pharma on Thursday said it has launched a novel fixed-dose combination of Trifluridine and Tipiracil, used to treat advanced colorectal and gastric cancer, in the country. The company has launched the product under the brand name Tipanat in a pack of
Announcement as on 18 November 2021

Announcements by Natco Pharm first page | Next page | Prev page |

524816 Natco Pharm current price & indicator signals

Moving Averages for Natco Pharm

  • 5Day Average: 983.51
  • 12Day Average: 947.92
  • 20Day Average: 908.5
  • 50Day Average: 883.12
  • 100Day Average: 872.05
  • 150Day Average: 871.36
  • 200Day Average: 884.65

524816 Indicators & signals

Indicator MACD (12,26,9)

952.98, 916.13, 24.96
Indicator MACD is in positive zone

Indicator ADX (14)

11.08, 32.76, 26.23
Indicator ADX is indicating that momentum is weak.
Indicator ADX is showing that momentum is towards buying

Indicator RSI (14)

Current RSI is: 59
Indicator RSI is indicating buying momentum and stock might rise.

Recent prices of 524816 Natco Pharm are as follows: Daily volume is divided by 10 day averaged volume

Date Close Range Change % Volume
06 Fri Mar 2026 1019.35 1000.70 to 1025.00 1.86% 0.26 times
05 Thu Mar 2026 1000.70 953.75 to 1003.70 5.03% 0.52 times
04 Wed Mar 2026 952.80 945.00 to 992.00 -0.38% 1.24 times
02 Mon Mar 2026 956.40 820.35 to 967.25 -3.23% 0.24 times
27 Fri Feb 2026 988.30 958.70 to 998.40 1.74% 0.52 times
26 Thu Feb 2026 971.40 963.95 to 994.70 -0.73% 0.43 times
25 Wed Feb 2026 978.55 942.85 to 990.45 3.61% 1.34 times
24 Tue Feb 2026 944.45 886.50 to 949.00 5.74% 4.59 times
23 Mon Feb 2026 893.20 887.00 to 906.10 0.27% 0.12 times
20 Fri Feb 2026 890.80 878.05 to 894.65 0.24% 0.27 times
19 Thu Feb 2026 888.70 881.00 to 931.15 -0.19% 0.72 times
18 Wed Feb 2026 890.40 863.20 to 898.35 0.67% 0.42 times

Videos related to: 524816 announcements Natco Pharm announcements and dividends declared BSE

Hindi Video Correct Way Of Fundamental Analysis Using EPS And PE - MunafaSutra

Hindi Video What Is Needed To Succeed In Stock Markets

524816 announcements Natco Pharm announcements and dividends declared BSE

 

Back to top